Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05601713
Other study ID # H-11-20-6234
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 28, 2022
Est. completion date May 4, 2023

Study information

Verified date May 2023
Source University of Ottawa
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The incidence and severity of hot weather and extreme heat events (heat waves) is increasing. As such, there is an urgent need to develop heat-alleviation strategies that can provide targeted protection for older adults who are at an elevated risk for heat-induced illnesses or death due to impaired body temperature and cardiovascular regulation. While air-conditioning provides the most effective protection from extreme heat, it is inaccessible for many individuals and cannot be used during power outages (e.g., heat-related rolling blackouts). Immersion of the lower limbs in cold water and/or the application of cold towels to the neck have been recommended as simple and sustainable alternatives to air-conditioning. However, empirical data to support the efficacy of these interventions for mitigating physiological strain and discomfort in older adults is lacking. To address this knowledge gap, this randomized crossover trial will evaluate the effect of lower limb immersion with and without application of cold towels to the neck on body core temperature, cardiovascular strain and autonomic function, dehydration, and thermal comfort in adults aged 65-85 years exposed to simulated heat wave conditions (38°C, 35% relative humidity) for 6 hours.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date May 4, 2023
Est. primary completion date May 4, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 65 Years to 85 Years
Eligibility Inclusion Criteria: - Male or female adults. - Aged 65-85 years. - Non-smoking. - English or French speaking. - Ability to provide informed consent. Exclusion Criteria: - Physical restriction (e.g., due to disease: intermittent claudication, renal impairment, active proliferative retinopathy, unstable cardiac or pulmonary disease, disabling stroke, severe arthritis, etc.). - Use of or changes in medication judged by the patient or investigators to make participation in this study inadvisable (e.g., medications increasing risk of heat-related illness; beta blockers, anticholinergics, etc.) - Cardiac abnormalities identified via 12-lead ECG during an incremental exercise test to volitional fatigue (performed for all participants). - Peak aerobic capacity (VO2peak), as measured during an incremental exercise test to volitional fatigue, exceeding the 50th percentile of age- and sex-specific normative values published by the American College of Sports Medicine (ACSM).

Study Design


Intervention

Other:
No cooling (control)
Participants are exposed to 38°C, 35% relative humidity for 6 hours without cooling interventions (control condition). Drinking water is available ad libitum.
Lower limb immersion
Participants are exposed to 38°C, 35% relative humidity for 6 hours. For the last 40 min of each hour, participants lower limbs are immersed in cool water (~20°C) up to the level of mid calf. Drinking water is available ad libitum.
Lower limb immersion + neck cooling
Participants are exposed to 38°C, 35% relative humidity for 6 hours. For the last 40 min of each hour, participants lower limbs are immersed in cool water (~20°C) up to the level of mid calf. During limb immersion, a towel soaked in cool water (~20°C) is placed around the participants neck. The towel is re-wet half way through the 40-min limb immersion. Drinking water is available ad libitum.

Locations

Country Name City State
Canada University of Ottawa Ottawa Ontario

Sponsors (1)

Lead Sponsor Collaborator
University of Ottawa

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Core temperature Rectal temperature measured as an index of core temperature (15 minute average) End of heat exposure (hour 6)
Secondary Heart rate Heart rate derived from 3-lead electrocardiogram (15 minute average) End of heat exposure (hour 6)
Secondary Systolic blood pressure Systolic blood pressure measured in triplicate via automated oscillometry (~60 seconds between measures) End of heat exposure (hour 6)
Secondary Diastolic blood pressure Diastolic blood pressure measured in triplicate via automated oscillometry (~60 seconds between measures) End of heat exposure (hour 6)
Secondary Rate pressure product Rate pressure product, an index of myocardial work and strain, calculated as systolic blood pressure x heart rate. End of heat exposure (hour 6)
Secondary Heart rate variability: SDNN Standard deviation of normal-to-normal RR intervals (SDNN) measured during 5 minutes of paced breathing (15 breaths/min) with participants in the seated position. SDNN will be evaluated twice, during two paced breathing periods (separated by 4 min of seated rest). End of heat exposure (hour 6)
Secondary Heart rate variability: RMSSD Root mean squared standard deviation of normal-to-normal RR intervals (RMSSD) measured during 5 minutes of paced breathing (15 breaths/min) with participants in the seated position. RMSSD will be evaluated twice, during two paced breathing periods (separated by 4 min of seated rest). End of heat exposure (hour 6)
Secondary Cardiac response to standing from supine (30:15 ratio) Cardiac response to standing evaluated as the ratio between the highest RR interval (lowest heart rate) measured at the 30th heart beat after standing from supine (+/- 5 beats) and the lowest RR interval (highest heart rate) measured at the 15th heart beat after standing (+/- 5 beats). Cardiac response to standing will be evaluated twice, during two lying-to-standing tests (separated by 10 min of supine rest). End of heat exposure (hour 6)
Secondary Systolic response to standing from supine Systolic blood pressure response to standing evaluated as the difference in blood pressure measured between the standing and supine. Standing systolic blood pressure will be taken as the lowest value of those measured after 60 and 120 seconds of standing. Systolic response to standing will be evaluated twice, during two lying-to-standing tests (separated by 10 min of supine rest). End of heat exposure (hour 6)
Secondary Integrated baroreflex sensitivity (sit-to-stand maneuvers) Determined from beat-to-beat arterial pressures and heart rate (volume-clamp technique) during 5 min of sit-to-stand maneuvers performed at 0.05 Hz (3 cycles per min; 15 total cycles). End of heat exposure (hour 6)
Secondary Fluid consumption Cumulative fluid consumption calculated by weighing participant water intake at the start and end of each hour of exposure. End of heat exposure (hour 6)
Secondary Fluid loss Fluid loss calculated as the change in body mass during each exposure presented as a percentage of baseline body mass (corrected for food consumption) End of heat exposure (hour 6)
Secondary Change in plasma volume Change in plasma volume from baseline values calculated from duplicate measurements of hemoglobin and hematocrit at the start and end of each exposure using the technique by Dill and Costill. End of heat exposure (hour 6)
Secondary Thermal comfort Thermal comfort assessed via a visual analog scale ("How comfortable does your body temperature feel?") ranging from extremely uncomfortable to extremely comfortable (midpoint: neutral). End of heat exposure (hour 6)
Secondary Orthostatic intolerance symptoms assessment Cumulative sum of scores on 6 questions asking participant to rank symptoms associated with orthostatic intolerance during the last 1-2 hours (including the lying-to-standing and sit-to-stand tests). All symptoms scored on a scale from 0 (none) to 10 (worst possible) and include feelings of: (1) "dizziness, lightheadedness, feeling faint, or feeling like you might black out"; (2) "Problems with vision (blurring, seeing spots, tunnel vision, etc.)"; (3) "Weakness"; (4) "Fatigue"; (5) "Trouble concentrating"; and (6) "Head and neck discomfort". End of heat exposure (hour 6)
See also
  Status Clinical Trial Phase
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Recruiting NCT06032065 - SMART Exercise for PAD Phase 3
Active, not recruiting NCT05293730 - Trial of the Impact of the Electronic Frailty Integrated With Social Needs N/A
Recruiting NCT03932162 - Gene Expression Changes In Young and Geriatric Skin Early Phase 1
Completed NCT04064528 - Effects of Age on Amino Acid Delivery to Tendon N/A
Active, not recruiting NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT06029920 - Influence of Overground Walking on Biomarkers, Cognitive Function, and Quality of Life in Elderly With Mild Cognitive Impairment N/A
Recruiting NCT05543980 - Leg Heat Therapy in Elderly Individuals Phase 2
Recruiting NCT05566938 - Study to Design a Precision Nutrition Strategy at a Group Level in the Elderly N/A
Completed NCT04894929 - Comprehensive Geriatric Assessment in the Monitoring of Functional Improvement N/A
Not yet recruiting NCT06071130 - Emotion, Aging, and Decision Making N/A
Enrolling by invitation NCT04641663 - Multi-target Dietary Supplement Tolerability in an Aging Population (MTDSST) N/A
Completed NCT04088006 - The Evaluation of Efficacy and Safety of Hyaluronic Acid Injection on Skin Moisturization and Elasticity N/A
Completed NCT03695081 - Patient Pathway Pharmacist - Optimal Drug-related Care N/A
Recruiting NCT05424263 - Acetate and Age-associated Arterial Dysfunction Phase 2
Completed NCT04551339 - Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19 N/A
Recruiting NCT04997577 - Speech Perception and High Cognitive Demand N/A
Completed NCT05922475 - Efficacy of Pre-sleep or Post-exercise Protein During 12 Weeks of Resistance Exercise Training N/A
Completed NCT04015479 - Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults N/A
Recruiting NCT06133634 - Fisetin to Improve Vascular Function in Older Adults Phase 1/Phase 2